These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19156238)

  • 1. Treating acute "no-reflow" with intracoronary adenosine in 4 patients during percutaneous coronary intervention.
    Forman MB; Hou D; Jackson EK
    Tex Heart Inst J; 2008; 35(4):439-46. PubMed ID: 19156238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention.
    Huang RI; Patel P; Walinsky P; Fischman DL; Ogilby JD; Awar M; Frankil C; Savage MP
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):671-6. PubMed ID: 17034064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning.
    Parikh KH; Chag MC; Shah KJ; Shah UG; Baxi HA; Chandarana AH; Naik AM; Shah JN; Shah HD; Goyal RK
    Can J Physiol Pharmacol; 2007; 85(3-4):476-82. PubMed ID: 17612657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.
    Hillegass WB; Dean NA; Liao L; Rhinehart RG; Myers PR
    J Am Coll Cardiol; 2001 Apr; 37(5):1335-43. PubMed ID: 11300444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotective effect of high-dose intragraft adenosine infusion on microvascular function and prevention of no-reflow during saphenous vein grafts intervention.
    Kapoor N; Yalamanchili V; Siddiqui T; Raza S; Leesar MA
    Catheter Cardiovasc Interv; 2014 Jun; 83(7):1045-54. PubMed ID: 24307656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction.
    Tesic MB; Stankovic G; Vukcevic V; Ostojic MC
    Herz; 2010 Mar; 35(2):114-8. PubMed ID: 20376646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perforated balloon technique: A simple and handy technique to combat no-reflow phenomenon in coronary system.
    Patel T; Shah S; Gulati R; Kwan T; Cohen MG; Pancholy S
    Catheter Cardiovasc Interv; 2018 Nov; 92(5):890-894. PubMed ID: 29280545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of PercuSurge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention.
    Youssef AA; Wu CJ; Hang CL; Cheng CI; Yang CH; Chen CJ; Chen YH; Chai HT; Chua S; Yeh KH; Yip HK
    Circ J; 2006 Dec; 70(12):1538-42. PubMed ID: 17127795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.
    Fokkema ML; Vlaar PJ; Vogelzang M; Gu YL; Kampinga MA; de Smet BJ; Jessurun GA; Anthonio RL; van den Heuvel AF; Tan ES; Zijlstra F
    Circ Cardiovasc Interv; 2009 Aug; 2(4):323-9. PubMed ID: 20031735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention.
    Movahed MR; Butman SM
    Cardiovasc Revasc Med; 2008; 9(1):56-61. PubMed ID: 18206640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.
    Amit G; Cafri C; Yaroslavtsev S; Fuchs S; Paltiel O; Abu-Ful A; Weinstein JM; Wolak A; Ilia R; Zahger D
    Am Heart J; 2006 Nov; 152(5):887.e9-14. PubMed ID: 17070151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction.
    Shinozaki N; Ichinose H; Yahikozawa K; Shimada H; Hoshino K
    Int Heart J; 2007 Jul; 48(4):423-33. PubMed ID: 17827814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon.
    Barcin C; Denktas AE; Lennon RJ; Hammes L; Higano ST; Holmes DR; Garratt KN; Lerman A
    Catheter Cardiovasc Interv; 2004 Apr; 61(4):484-91. PubMed ID: 15065143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with a novel intracoronary perfusion catheter to treat no-reflow phenomenon in acute coronary syndromes.
    Maluenda G; Ben-Dor I; Delhaye C; Gonzalez MA; Collins SD; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
    J Interv Cardiol; 2010 Apr; 23(2):109-13. PubMed ID: 20337859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The no-reflow phenomenon and its clinical significance].
    Sidorenko GI; Ostrovskiĭ IuP
    Kardiologiia; 2002; 42(5):74-80. PubMed ID: 12494153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory no-reflow successfully treated with local infusion of high-dose adenosine and verapamil--a case report.
    Dillon WC; Hadian D; Ritchie ME
    Angiology; 2001 Feb; 52(2):137-41. PubMed ID: 11228087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distal filter protection during percutaneous coronary intervention in native coronary arteries and saphenous vein grafts in patients with acute coronary syndromes.
    Pasquetto G; Reimers B; Favero L; Saccà S; Cernetti C; Napodano M; Piccolo P; Pascotto P
    Ital Heart J; 2003 Sep; 4(9):614-9. PubMed ID: 14635379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No-Reflow Complicating Chronic Total Occlusion Coronary Revascularization.
    Dall'Ara G; Testa L; Tumscitz C; Mattesini A; Gasparini GL; Grotti S; Bollati M; Tarantino F; Di Mario C; Oreglia JA
    J Invasive Cardiol; 2020 Feb; 32(2):58-63. PubMed ID: 32005785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine.
    Fischell TA; Carter AJ; Foster MT; Hempsall K; DeVries J; Kim DH; Kloostra A
    Cathet Cardiovasc Diagn; 1998 Dec; 45(4):360-5. PubMed ID: 9863736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon.
    Assali AR; Sdringola S; Ghani M; Denkats AE; Yepes A; Hanna GP; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Catheter Cardiovasc Interv; 2000 Sep; 51(1):27-31; discussion 32. PubMed ID: 10973014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.